Numerous pharmaceutical companies are considering Iran as a strong site for clinical research. With a huge untapped population, the opportunity to conduct all clinical Phases from I-IV, a clear process of regulatory application, and the potential to run genetic and observational studies, it is fast becoming a popular location for trials. Adhiti Sharad Kumar of ACRP explicates the registration process, regulatory and ethical stipulations, procedures, and timelines for conducting clinical research in this emerging region.
http://jforcs.com/jcs/wp-content/uploads/2014/02/Iran-Interest.pdf